NextCure is a clinical-stage biopharmaceutical company focused on oncology and select other therapeutic areas. The company's pipeline comprises multiple product candidates in development, including LNCB74, a B7-H4-targeted antibody-drug conjugate designed to kill tumor cells, and NC410, a LAIR-2 fusion protein intended to block immune suppression mediated by LAIR-1. Additional oncology candidates include NC525, a LAIR-1 antibody targeting acute myeloid leukemia, and SIM0505, a CDH6-targeted antibody-drug conjugate for solid tumors. The company also develops NC605, a Siglec-15-targeting antibody for potential use in chronic bone diseases including osteoarthritis and non-union fractures, and NC181, a humanized antibody targeting ApoE4 for Alzheimer's disease.
As a clinical-stage entity, NextCure does not currently generate revenue from product sales. The company operates with a research and development focus across its candidate portfolio. Headquartered in Beltsville, Maryland, NextCure operates with a small team of 43 full-time employees. The company is incorporated in Delaware and listed on the Nasdaq stock exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.99 | $-1.99 | +11.6% | |
| 2023 | $-2.25 | $-2.25 | +16.4% | |
| 2022 | $-2.69 | $-2.69 | -7.2% | |
| 2021 | $-2.51 | $-2.51 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-06 | 0001558370-25-002402 | SEC ↗ |
| 2023-12-31 | 2024-03-21 | 0001558370-24-003672 | SEC ↗ |
| 2022-12-31 | 2023-03-02 | 0001558370-23-002698 | SEC ↗ |
| 2021-12-31 | 2022-03-03 | 0001558370-22-002824 | SEC ↗ |
| 2020-12-31 | 2021-03-04 | 0001558370-21-002384 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001558370-20-002566 | SEC ↗ |